A5062825571- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Research Studies
- Esophageal Cancer Research and Treatment
- Ovarian cancer diagnosis and treatment
- Colorectal and Anal Carcinomas
- Brain Metastases and Treatment
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Breast Lesions and Carcinomas
- Metastasis and carcinoma case studies
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Gastric Cancer Management and Outcomes
- Esophageal and GI Pathology
Ningbo Medical Center Lihuili Hospital
2021-2024
Ningbo University
2021-2024
Anhui Medical University
2016
307th Hospital of Chinese People’s Liberation Army
2016
Background Studies on the prognostic factors for patients with brain oligo-metastasis treated fractionated stereotactic radiotherapy (FSRT) usually focus size of metastatic tumor and radiation dose. Some inflammatory indicators have predictive value in non-small cell lung cancer (NSCLC) metastasis receiving radiotherapy. However, NSCLC FSRT, their effect dose is unknown. Methods A total 95 advanced who had undergone FSRT treatment at Ningbo Medical Center Lihuili Hospital between January...
Various inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR), have been well authenticated to predict clinical outcomes in numerous types of cancer. The optimal treatment for patients with locally advanced esophageal squamous cell carcinoma (ESCC) located middle or upper region is still inconclusive. aim study was examine pretreatment NLR PLR select from radical surgery definitive chemoradiotherapy (dCRT) these patients. linkage between...
Anlotinib is a third-line or further therapy for advanced non-small-cell lung cancer (NSCLC). However, the lack of simple biomarkers to predict curative effect anlotinib creates significant unmet needs in exploring markers. This study aimed explore relationship between prognostic nutritional index (PNI) and its variations efficacy anlotinib.Data patients with NSCLC who received were collected at Ningbo Medical Center Lihuili Hospital. The data included values pretreatment PNI (pre-PNI),...
Background. A phase III randomized multicenter trial (ALTER0303) reported anlotinib to be significantly beneficial patient survival. An array of inflammatory biomarkers, such as neutrophil lymphocyte ratio (NLR) and platelet (PLR), are associated with the response treatment in numerous types cancer. However, we found few studies investigating predictive value NLR or PLR advanced NSCLC anlotinib. Thus, our objective was examine relationship between effect, well individuate stratification...
Abstract Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense treatment non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patients. Although numerous inflammatory biomarkers have been shown to play vital roles treatment, clinical significance blood lipid levels before has not evaluated. Here, research aims explore relationship...
Abstract Background According to the randomized multicenter phase II trial (ALTER1202), anlotinib has been approved as a third‐line therapy for advanced small‐cell lung cancer (SCLC). Some studies showed predictive function of inflammatory markers, including neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte (PLR), and lymphocyte‐to‐monocyte (LMR) in different cancers treated with anti‐vascular targeting drugs. However, none roles NLR, PLR, LMR SCLC patients receiving anlotinib....
ABSTRACT Background Endoscopic submucosal dissection (ESD) is a widely utilized treatment for early esophageal cancer. However, the rising incidence of postoperative stricture poses significant challenge, adversely affecting patients' quality life and outcomes. Developing precise predictive models urgently required to enhance Materials Methods This study retrospectively analyzed clinical data from 124 patients with cancer who underwent ESD at Ningbo Medical Center Lihuili Hospital. Patients...
Objective To evaluate the effects and significance of adjuvant radiotherapy after neoadjuvant chemotherapy on local recurrence (LR) rate in patients with stage T1-2N1M0 breast cancer. Methods Clinical data were collected from cancer who admitted to our hospital treated 2005 2010. The clinical outcomes those analyzed treatment radiotherapy. A total 144 a median age 45 years (23-72 years) enrolled as subjects. Results In patients, 30 (21%) had pathological complete response (pCR)...
Abstract Background Studies on the prognostic factors for patients with brain oligo-metastasis treated fractionated stereotactic radiotherapy (FSRT) usually focus size of metastatic tumor and radiation dose. Some inflammatory indicators have predictive value in non-small cell lung cancer (NSCLC) metastasis receiving radiotherapy. However, NSCLC FSRT, their effect dose is unknown. Methods A total 95 advanced who had undergone FSRT treatment at Ningbo Medical Center Lihuili Hospital between...
Abstract Background: Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense treatment non-small cell lung cancer (NSCLC). Results from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patients. Although numerous inflammatory biomarkers play vital role treatment, none them has focused on blood lipids before treatment. Here, we explored relationship between and efficacy anlotinib, with view...